Kdm6b confers Tfdp1 with the competence to activate p53 signalling in regulating palatogenesis

Tingwei Guo, Xia Han, Jinzhi He, Jifan Feng, Junjun Jing, Eva Janečková, Jie Lei, Thach-Vu Ho, Jian Xu and Yang Chai*

Center for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA 90033, USA

Corresponding author:

Yang Chai
University Professor
George and MaryLou Boone Chair in Craniofacial Biology
Center for Craniofacial Molecular Biology
University of Southern California
2250 Alcazar Street – CSA 103
Los Angeles, CA 90033
Phone number: 323-442-3480
ychai@usc.edu

Key words: *Kdm6b*, epigenetic regulation, *p53*, H3K27me3, *Tfdp1*, palatogenesis

33 Abstract

34 Epigenetic regulation plays extensive roles in diseases and development. Disruption of epigenetic
 35 regulation not only increases the risk of cancer, but can also cause various developmental defects.
 36 However, it is still unclear how epigenetic regulators coordinate with tissue-specific regulatory factors
 37 during morphogenesis of specific organs. Using palatogenesis as a model, we reveal the functional
 38 significance of *Kdm6b*, a H3K27me3 demethylase, in regulating embryonic development. Our study
 39 shows that *Kdm6b* plays an essential role in neural crest development, and loss of *Kdm6b* disturbs p53
 40 pathway-mediated activity, leading to complete cleft palate along with cell proliferation and
 41 differentiation defects. Furthermore, activity of H3K27me3 on the promoter of *p53* is precisely controlled
 42 by *Kdm6b*, and *Ezh2* in regulating p53 expression in cranial neural crest cells. More importantly, *Kdm6b*
 43 renders chromatin accessible to the transcription factor Tfdp1, which binds to the promoter of *p53* along
 44 with Kdm6b to specifically activate *p53* expression during palatogenesis. Collectively our results highlight
 45 the important role of the epigenetic regulator Kdm6b and how it cooperates with Tfdp1 to achieve its
 46 functional specificity in regulating *p53* expression, and further provide mechanistic insights into the
 47 epigenetic regulatory network during organogenesis.

48

49

50 **Introduction**

51 Embryonic development is a highly complex self-assembly process during which precursor cells are
 52 coordinated to generate appropriate cell types and assemble them into well-defined structures, tissues, and
 53 organs (Shahbazi et al. 2016). During this process, precursor cells undergo extensive and rapid cell
 54 proliferation until they reach the point of exit from the cell cycle to differentiate into various cell lineages
 55 (Ruijtenberg and van den Heuvel 2016; Miermont et al. 2019). How these precursor cells modulate
 56 expression of different genes and proceed through diverse proliferation and differentiation processes is a
 57 very complex and interesting question. Growing evidence shows that epigenetic regulation, which
 58 includes mechanisms such as DNA methylation, histone modifications, chromatin accessibility, and
 59 higher-order organization of chromatin, provides the ability to modify gene expression and associated
 60 protein production in a cell type-specific manner, thus playing an essential role in achieving signaling
 61 specificity and in regulating cell fate during embryonic development (Hanna et al. 2018).

62 Among these various layers of epigenetic regulation, DNA methylation and histone methylation are the
 63 best-characterized and known to be key regulators of diverse cellular events (Bannister and Kouzarides
 64 2011; Smith and Meissner 2013; Molina-Serrano et al. 2019). For example, methylation of lysine 27 on
 65 histone H3 (H3K27me) by methyltransferases is a feature of heterochromatin that renders it inaccessible
 66 to transcription factors, thus maintaining transcriptional repression, across many species (Wiles and Selker
 67 2017). On the other hand, methylation of H3K4me3 found near the promoter region can couple with the
 68 NURF complex to increase chromatin accessibility for gene activation (Wysocka et al. 2006; Soares et al.
 69 2017). Demethylation, which results from removing a methyl group, also plays important roles during
 70 development. For instance, demethylation of H3K4 is required for maintaining pluripotency in embryonic
 71 stem cells, and demethylases KDM6A and KDM6B are required for proper gene expression in mature T
 72 cells (Lessard and Crabtree 2010; Jambhekar et al. 2019). These studies clearly show that failure to

73 maintain epigenomic integrity can cause deleterious consequences for embryonic development and adult
74 tissue homeostasis (Henckel et al. 2007; Kim et al. 2009; Kang et al. 2019).

75 Palatogenesis is a complex process known to be regulated by multiple genetic regulatory mechanisms,
76 including several signaling pathways (BMP, SHH, WNT, FGF, and TGF β) and different transcription
77 factors (such as *Msx1*, *Sox9*, *Lhx6/8*, *Dlx5*, *Shox2* and more) (Satokata and Maas 1994; Yu et al. 2005;
78 Chai and Maxson 2006; Levi et al. 2006; Cobourne et al. 2009; Lee and Saint-Jeannet 2011; Nakamura et
79 al. 2011; Bush and Jiang 2012; He and Chen 2012; Parada and Chai 2012; Xu et al. 2016; Reynolds et al.
80 2019). However, environmental effects can also contribute to orofacial defects, which lends further
81 support to the notion that genetic factors are not sufficient to fully explain the etiology of many birth
82 defects (Dixon et al. 2011; Roessler et al. 2012; Seelan et al. 2012). Furthermore, case studies have
83 revealed that heterozygous mutation of a chromatin-remodeling factor, *SATB2*, and variation in DNA
84 methylation can cause cleft palate in patients (Leoyklang et al. 2007; Chandrasekharan and Ramanathan
85 2014; Young et al. 2021). These cases have drawn our attention to the function of epigenetic regulation in
86 palatogenesis.

87 The contribution of cranial neural crest cells (CNCCs) is critical to palate mesenchyme formation.
88 Recently, studies have begun to address the role of epigenetic regulation in neural crest cell fates
89 determination during development. For instance, homozygous loss of *Arid1a*, a subunit of SWI/SNF
90 chromatin remodeling complex, in neural crest cells results in lethality in mice, associated with severe
91 defects in the heart and craniofacial bones (Chandler and Magnuson 2016). In addition, both lysine
92 methyltransferase *Kmt2a* and demethylase *Kdm6a* are essential for cardiac and neural crest development
93 (Shpargel et al. 2017; Sen et al. 2020). However, how these epigenetic changes lead to tissue-specific
94 response during neural crest fate determination remain to be elucidated.

95 In this study, using palatogenesis as a model we investigated the functional significance of the demethylase
 96 *Kdm6b* in regulating the fate of CNCCs during palatogenesis. We have discovered that loss of *Kdm6b* in
 97 CNC-derived cells results in complete cleft palate along with soft palate muscle defects. We also found
 98 cell proliferation and differentiation defects of CNC-derived cells in *Kdm6b* mutant mice. More
 99 importantly, our study shows that the level of H3K27me3 on the promoter of *p53* is precisely controlled
 100 by *Kdm6b*, and *Ezh2* in regulating expression of *p53* (also known as *Trp53*). Furthermore, the transcription
 101 factor Tfdp1 binds to the promoter of *p53* along with *Kdm6b* to specifically activate the expression of this
 102 tumor suppressor gene. Our study highlights the importance of epigenetic regulation on cell fate decision
 103 and its function in regulating activity of *p53* in CNC-derived cells during organogenesis.

104

Results

Loss of *Kdm6b* in CNC-derived cells results in craniofacial malformations

Previous research has shown that the X-chromosome-linked H3K27 demethylase Kdm6a is indispensable for neural crest cell differentiation and viability as it establishes appropriate chromatin structure (Schwarz et al. 2014; Shpargel et al. 2017). However, we do not yet have a comprehensive understanding of the roles of two other members of the Kdm6 family, *Kdm6b* and *Uty*, in regulating CNCCs during craniofacial development. More importantly, we have yet to understand how demethylase achieves its functional specificity in regulating downstream target genes. In order to elucidate the functions of *Kdm6b* and *Uty*, we first evaluated the expression patterns of Kdm6 family members in the palatal region (Figure 1-figure supplement 1A-F). We found that, of these, *Kdm6b* is more abundantly expressed than *Kdm6a* and *Uty* in both palate mesenchymal and epithelial cells, which indicated it might play a critical role in regulating palatogenesis.

To investigate the tissue-specific function of *Kdm6b* during craniofacial development, we generated *Wnt1-Cre;Kdm6b^{fl/fl}* and *K14-Cre;Kdm6b^{fl/fl}* mice to specifically target the deletion of *Kdm6b* in CNC-derived and epithelial cells, respectively. Loss of *Kdm6b* in CNC-derived cells resulted in complete cleft palate in *Wnt1-Cre;Kdm6b^{fl/fl}* mice (90% phenotype penetrance, N = 7) and postnatal lethality at newborn stage (100% phenotype penetrance, N = 7) without interrupting expression of other Kdm6 family members (Figure 1-figure supplement 1A-N and Figure 1A-B). To evaluate when *Kdm6b* was inactivated in the CNC-derived cells, we also investigated the expression of *Kdm6b* at E9.5, well prior to the formation of the palate primordium, and found that *Kdm6b* was efficiently inactivated in the CNC-derived cells at this stage (Figure 1-figure supplement 1O-P). Interestingly, loss of *Kdm6b* in epithelial cells did not lead to obvious defects in the craniofacial region in *K14-Cre;Kdm6b^{fl/fl}* mice (Figure 1-figure supplement 2A-

127 H). These results emphasized that *Kdm6b* is specifically required in CNC-derived cells during
 128 palatogenesis. CT images also confirmed the complete cleft palate phenotype and revealed that the most
 129 severe defects in the palatal region of *Wnt1-Cre;Kdm6b^{fl/fl}* mice were hypoplastic palatine processes of
 130 the maxilla and palatine bones (Figure 1C-D). Except for a minor flattened skull, other CNC-derived
 131 bones did not show significant differences between control and *Wnt1-Cre;Kdm6b^{fl/fl}* mice (Figure 1-figure
 132 supplement 2I-N). To evaluate the phenotype in more detail, we performed histological analysis and found
 133 that although the palatal shelves were able to elevate, the maxilla and palatine bones, as well as the palate
 134 stromal mesenchyme and soft palate muscles, failed to grow towards the midline in *Wnt1-Cre;Kdm6b^{fl/fl}*
 135 mice (Figure 1G-R and Figure 1-figure supplement 3A-P). Furthermore, in the posterior soft palate region,
 136 *Wnt1-Cre;Kdm6b^{fl/fl}* mice also showed morphological defects related to the orientation of muscle fibers
 137 and the pterygoid plate (Figure 1-figure supplement 3A-X). However, since the soft palate forms
 138 subsequent to the hard palate, it is difficult to identify whether the soft palatal muscle phenotype is a
 139 primary defect or a consequence resulting from an anterior cleft. Therefore, we focused on the anterior
 140 hard palate for further investigation. Collectively, these data indicate that mesenchymal *Kdm6b* is
 141 indispensable for craniofacial development and plays an essential role during palatogenesis.

Figure 1. Loss of *Kdm6b* results in cleft palate

(A-B) Whole-mount oral view shows complete cleft palate phenotype in *Wnt1-Cre;Kdm6b^{fl/fl}* mice. Arrowhead in B indicates the cleft palate. Scale bar: 2 mm. (C-D) CT imaging reveals that the palatine process of the maxilla and palatine bone are missing in *Wnt1-Cre;Kdm6b^{fl/fl}* mice. White arrowheads in C indicates palatine process of maxilla in control mice, and red arrows indicates palatine bone. White

148 asterisk in D indicates missing palatine process of maxilla in *Wnt1-Cre;Kdm6b^{fl/fl}* mice and red asterisk
 149 in D indicates the missing palatine bone in *Kdm6b* mutant mice. Scale bars: 1 mm. (E-F) Sagittal views
 150 of CT images demonstrate the locations of HE sections in G-R. Red lines indicate the locations of sections.
 151 Yellow arrow in E indicates palatal shelf and yellow asterisk in F indicates cleft. Scale bars: 1 mm. (G-
 152 R) Histological analysis of control and *Wnt1-Cre;Kdm6b^{fl/fl}* mice. H, J, L, N, P, and R are magnified
 153 images of boxes in G, I, K, M, O, and Q, respectively. Asterisks in M, O, and Q indicate cleft in *Kdm6b*
 154 mutant mice. Scale bar: 200 μ m. Mes: mesenchyme; PPM: palatine process of maxilla; PB: palatine bone.

155

***Kdm6b* is critical for proliferation and differentiation of CNC-derived palatal mesenchymal cells.**

157 During craniofacial development, CNCCs migrate ventro-laterally and populate the branchial arches to
 158 give rise to distinct mesenchymal structures in the head and neck, such as the palate. Failure of CNCCs to
 159 populate pharyngeal arches causes craniofacial defects (Noden 1983; Noden 1991; Trainor and Krumlauf
 160 2000; Cordero et al. 2011). To determine whether *Kdm6b* mutant CNCCs successfully populate the first
 161 pharyngeal arch, which gives rise to the palatal shelves, we generated tdTomato reporter mice and
 162 collected samples at E10.5. The results showed that CNCCs migration was not adversely affected in
 163 *Kdm6b* mutant mice (Figure 2-figure supplement 4A-B). Then we evaluated the process of palatogenesis
 164 at different embryonic stages, and found that the cleft palate phenotype emerged as early as E14.5 in *Wnt1-
 165 Cre;Kdm6b^{fl/fl}* mice (Figure 2-figure supplement 4C-D). These data established that *Kdm6b* is not essential
 166 for CNCCs entering the pharyngeal arch but is specifically required in regulating post-migratory CNC-
 167 derived cells.

168 Because cell proliferation defects in CNC-derived cells frequently lead to craniofacial defects, we tested
 169 whether loss of *Kdm6b* can affect cell proliferation using EdU labeling. After 2 hours of EdU labeling, we
 170 found that the number of cells positively stained with EdU were significantly increased in the CNC-

171 derived palatal mesenchyme in *Wnt1-Cre;Kdm6b^{fl/fl}* mice compared to controls (Figure 2A-C). In addition,
 172 after 48 hours of EdU labeling, we found that the number of Ki67 and EdU double-positive cells was
 173 significantly increased in *Wnt1-Cre;Kdm6b^{fl/fl}* mice (Figure 2D-H). These results indicated that loss of
 174 *Kdm6b* in CNC-derived cells resulted in more cells remaining in the cell cycle and actively proliferating,
 175 which further led to hyperproliferation of mesenchymal cells in the palatal region of *Wnt1-Cre;Kdm6b^{fl/fl}*
 176 mice. Meanwhile, increased cell death in the palatal mesenchyme was observed in *Wnt1-Cre;Kdm6b^{fl/fl}*
 177 mice compared to controls, based on TUNEL staining analysis (Figure 2-figure supplement 4E-H).

178 Typically, cell proliferation and differentiation are inversely correlated. Differentiation of precursor cells
 179 is generally associated with arrested proliferation and permanently exiting the cell cycle (Ruijtenberg and
 180 van den Heuvel 2016). To test whether cell differentiation was affected in the CNC-derived palatal
 181 mesenchyme in *Wnt1-Cre;Kdm6b^{fl/fl}* mice, we examined the distribution of early osteogenesis markers
 182 Runx2 and later osteogenesis marker Sp7 in the palatal region from E13.5 to E15.5 (Figure 2I-P). There
 183 was a decrease in the number of Runx2⁺ cells in the palatal mesenchyme at both E13.5 and E14.5 in *Wnt1-*
 184 *Cre;Kdm6b^{fl/fl}* mice in comparison to the control (Figure 2I-L). In addition, Sp7⁺ cells were also decreased
 185 in *Wnt1-Cre;Kdm6b^{fl/fl}* mice at both E14.5 and E15.5 (Figure 2M-P). Furthermore, when we induced
 186 osteogenic differentiation in palatal mesenchymal cells from E13.5 embryos for three weeks, we found
 187 that cells from *Wnt1-Cre;Kdm6b^{fl/fl}* mice showed much less calcium deposition than cells from control
 188 mice, indicating a reduction in osteogenic potential in cells from *Kdm6b* mutant mice (Figure 2Q-U).
 189 These results indicated that *Kdm6b* was indispensable for maintaining normal proliferation and
 190 differentiation of CNC-derived cells.

Figure 2. *Kdm6b* is critical for proliferation and differentiation of CNC-derived palatal mesenchyme cells

(A-B) Immunostaining of EdU at E13.5 after 2 hours of EdU labeling. Dotted lines indicate palatal shelf region. Dashed lines indicate the palatal region used for quantification in C. Scale bar: 50 μ m. (C) Quantification of EdU⁺ cells represented in A and B. (D-G) Co-localization of EdU and Ki67 at E13.5 after 48 hours of EdU labeling. Dotted lines indicate palatal shelf region. Dashed lines indicate the palatal region used for quantification in H. F and G are magnified images of boxes in D and E. Arrows in F and G indicate representative cells that are only EdU⁺, while arrowheads indicate representative cells that are positive for both EdU and Ki67. Scale bar: 50 μ m. (H) Quantification of EdU and Ki67 double-positive cells represented in D and E. (I-L) Immunostaining of Runx2 at indicated stages. Insets are higher magnification images of boxes in I-L. Asterisks in J and L indicate decreased Runx2⁺ cells observed in *Wnt1-Cre;Kdm6b^{fl/fl}* mice. Scale bar: 50 μ m. (M-P) Immunostaining of Sp7 at indicated stages. Insets are higher magnification images of boxes in O and P. Asterisk in P indicates decreased Sp7⁺ cells observed in *Wnt1-Cre;Kdm6b^{fl/fl}* mice. Scale bar: 50 μ m. (Q-U) Osteogenic differentiation assay using Alizarin red S staining. U is the quantification result of Alizarin red S staining represented in Q and R. Scale bars: 2 mm in Q and R; 200 μ m in S and T.

Figure 2-Source data 1 for figure 2C

Figure 2-Source data 2 for figure 2H

Figure 2-source data 3 for figure 2U

Loss of *Kdm6b* in CNC-derived cells disturbs p53 pathway-mediated activity

In order to identify the downstream targets of *Kdm6b* in the palatal mesenchyme, we performed RNA-seq analysis of palatal tissue at E12.5. The results showed that more genes were downregulated than upregulated in the palatal mesenchyme in *Wnt1-Cre;Kdm6b^{fl/fl}* mice (Figure 3A), which is consistent with the function of *Kdm6b* in removing the repressive mark H3K27me3. We further used Ingenuity Pathway

Analysis (IPA) and Gene Ontology (GO) analysis to analyze the pathways that were most disturbed in the palatal mesenchyme in *Kdm6b* mutant mice. Surprisingly, both analyses indicated that pathways involving *p53* might be disturbed in the palatal mesenchyme in *Wnt1-Cre;Kdm6b^{fl/fl}* mice (Figure 3B-C).

The tumor suppressor *p53* plays prominent roles in regulating DNA damage response, including arresting cell growth for DNA repair, directing cellular senescence, and activating apoptosis (Mijit et al. 2020). Mutation of *p53* is a major cause of cancer development (Williams and Schumacher 2016). Previous research has shown that homozygous *p53* mutant mice exhibit craniofacial defects with complete cleft palate, while inappropriate activation of *p53* during embryogenesis also causes developmental defects including craniofacial abnormalities (Tateossian et al. 2015; Bowen et al. 2019). These results suggest that precise dosage of *p53* is indispensable for craniofacial development. We analyzed expression of *p53* in our samples and found that it significantly decreased in the palatal region of the *Kdm6b* mutant mice (Figure 3D-H). These results indicate that *Kdm6b* plays an important role in regulating the *p53* pathway in the CNC-derived mesenchyme during palatogenesis. To further evaluate the consequence of downregulated *p53* in *Wnt1-Cre;Kdm6b^{fl/fl}* mice, we assessed DNA damage, which are tightly related to the function of *p53*, in our study. We found that DNA damage increased, as indicated by γ H2AX expression, in the palatal mesenchyme in *Wnt1-Cre;Kdm6b^{fl/fl}* mice (Figure 3I-M). More importantly, we observed significantly increased γ H2AX foci in the EdU⁺ cells of *Wnt1-Cre;Kdm6b^{fl/fl}* palatal mesenchyme (Figure 3N-R). These data indicated that actively proliferating cells in *Wnt1-Cre;Kdm6b^{fl/fl}* mice experienced more severe DNA damage compared to those in the control mice, which might be the result of replication stress caused by the hyperproliferation we observed in *Wnt1-Cre;Kdm6b^{fl/fl}* mice. Collectively, these results suggest that *p53*'s function in DNA damage response is impaired in *Wnt1-Cre;Kdm6b^{fl/fl}* mice. Furthermore, without appropriate activation of *p53*, cells of the palatal mesenchyme

239 escaped from proper cell cycle arrest for DNA damage repair, which resulted in increased DNA damage
240 in the *Kdm6b* mutant mice.

241
242 **Figure 3. p53 signaling pathway is disturbed in *Wnt1-Cre;Kdm6b*^{fl/fl} mice**

243 (A) Bulk RNA-seq result of palatal tissues collected at E12.5 is represented in heatmap. Differentially
244 expressed genes are selected using $P < 0.05$ and fold change < -1.2 or > 1.2 . (B) IPA analysis using of
245 bulk RNA-seq result. Red box indicates the top upregulated pathway observed in *Wnt1-Cre;Kdm6b*^{fl/fl}
246 sample. (C) GO analysis using bulk RNA-seq result. Red box indicates p53 signaling is one of the top 10
247 pathways. Y-axis shows the percentage of genes hit against total number of pathways hit. (D-G)
248 Expression of *p53* at E13.5 using RNAscope *in situ* hybridization. Dotted lines in D and F indicate palatal

shelf. E and G are magnified images of boxes in D and F. Asterisk in G indicates decreased expression of *p53* observed in *Wnt1-Cre;Kdm6b^{fl/fl}* mice. Scale bar: 50 μ m. (H) RT-qPCR quantification of *p53* in palatal tissues collected at E13.5. Asterisk indicates $P < 0.05$. (I-L) Immunostaining of γ H2AX at E13.5. Dotted lines in I and K indicate palatal shelf and dashed lines indicate quantification area. J and L are magnified images of boxes in I and K, respectively. Arrowheads in J and L indicate representative γ H2AX+ cells. Scale bar: 50 μ m. (M) Quantification of γ H2AX+ cells represented in I and K. Asterisk indicates $P < 0.05$. (N-Q) Co-localization of EdU and γ H2AX at E13.5 after 2 hours of EdU labeling. Dotted lines in N and P indicate palatal shelf region, while dashed lines indicate the palatal region used for quantification in R. O and Q are magnified images of boxes in N and P. Red arrows in O and Q indicate representative EdU+ cells with less than 5 γ H2AX foci, while white arrowheads indicate representative cells that are positive for EdU and with >5 γ H2AX foci. Scale bar: 50 μ m. (R) Quantification of EdU+ cells with >5 γ H2AX foci represented in N and P. Asterisk indicates $P < 0.05$.

Figure 3-Source data 1 for figure 3H

Figure 3-Source data 2 for figure 3M

Figure 3-Source data 3 for figure 3R

Altered *p53* expression is responsible for the developmental defects in *Wnt1-Cre;Kdm6b^{fl/fl}* mice

To further test whether downregulated expression of *p53* is a key factor in the developmental defects we observed in *Wnt1-Cre;Kdm6b^{fl/fl}* mice, we transfected palatal mesenchymal cells from control mice with siRNA to knock down *p53*. qPCR revealed that expression of *p53* was significantly decreased in the cells treated with siRNA after three days (Figure 4-figure supplement 5A). At the same time, the group transfected with siRNA for *p53* showed a significant increase in EdU+ cells (Figure 4A-C). In addition, significantly increased γ H2AX+ cells were also observed in the group transfected with siRNA for *p53*

(Figure 4D-F). These data suggested that downregulated expression of *p53* in the palatal mesenchymal cells is a key factor that led to the hyperproliferation and increased DNA damage we observed in *Wnt1-Cre;Kdm6b^{fl/fl}* mice. Furthermore, both expression of *Runx2* and *Sp7* were also significantly reduced in the palatal mesenchymal cells transfected with siRNA for *p53* (Figure 4-figure supplement 5B-C), which indicated that downregulated expression of *p53* in the palatal mesenchymal cells resulted in differentiation defects, which were also observed in *Wnt1-Cre;Kdm6b^{fl/fl}* mice.

To further investigate the function of *p53* in *Wnt1-Cre;Kdm6b^{fl/fl}* mice, we tried to increase *p53* in *Kdm6b* mutant mice using available small molecules. Previous research showed that MDM2, a ubiquitin ligase, specifically targets *p53* for degradation and there is increased *p53* activity in *Mdm2* mutant mice, which exhibit a range of developmental defects (Arya et al. 2010; Bowen and Attardi 2019; Bowen et al. 2019). Nutlin-3, an MDM2 inhibitor that can specifically interrupt interaction between MDM2 and *p53*, increases *p53* in mouse primary neural stem progenitor cells and rescues neurogenic deficits in *Fmr1* KO mice (Li et al. 2016). We treated pregnant mice with Nutlin-3 at a dosage based on their body weight at E10.5, E12.5 and E14.5 of pregnancy and then collected samples at E16.5 for analysis. To assess the potential influence of the solvent used to dissolve Nutlin-3 (10% DMSO in corn oil), we also treated mice with 10% DMSO in corn oil at the same embryonic stages. None of the *Kdm6b* mutant mice were rescued after this treatment (N=3) (Figure 4-figure supplement 5D-E). In contrast, Nutlin-3 treatment successfully rescued the cleft palate observed in *Wnt1-Cre;Kdm6b^{fl/fl}* mice (N = 5) (Figure 4G-R). Western blot showed that the protein level of *p53* was successfully restored in the Nutlin-3-treated group (Figure 4-figure supplement 5F). This result further revealed that downregulation of *p53* in *Wnt1-Cre;Kdm6b^{fl/fl}* mice plays an essential role in the palatal defects and genetic interaction between *Kdm6b* and *p53*, and that it is important for the development of post-migratory CNCCs.

Figure 4. Altered *p53* expression is responsible for the developmental defects in *Wnt1-Cre;Kdm6b^{fl/fl}* mice

(A-C) Cells collected from E13.5 palatal tissue are transfected with siRNA to knock down expression of *p53*. Cell proliferation is evaluated using EdU labeling 3 days after transfection. A and B show

proliferation of cells assessed by EdU labeling. Difference in EdU+ cells between mock- and siRNA-transfected groups is quantified in C. Scale bar: 100 μ m. Asterisk indicates $P < 0.05$. (D-F) Cells collected from E13.5 palatal tissue are transfected with siRNA to knock down expression of *p53*. DNA damage is evaluated using γ H2AX 3 days after transfection. D and E show γ H2AX+ cells. Difference in γ H2AX+ cells between mock- and siRNA-transfected groups is quantified in F. Scale bar: 100 μ m. Asterisk indicates $P < 0.05$. (G-R) Histological analysis of control and *Wnt1-Cre;Kdm6b^{fl/fl}* mice treated with Nutlin-3. J, K, L, P, Q, and R are magnified images of boxes in G, H, I, M, N, and O, respectively. Scale bar: 200 μ m. Mes: mesenchyme; PPM: palatine process of maxilla; PB: palatine bone.

Figure 4-Source data 1 for figure 4C

Figure 4-Source data 2 for figure 4F

Level of H3K27me3 is precisely regulated by *Kdm6b* and *Ezh2* during palatogenesis

The lysine-specific demethylase *Kdm6b* is able to activate gene expression via removing the H3K27me3 repressive mark (Jiang et al. 2013). To investigate whether *Kdm6b* regulates the expression of *p53* through modifying the level of H3K27me3, we first examined the status of H3K27me3 in our samples and found that loss of *Kdm6b* in CNC-derived cells resulted in accumulation of H3K27me3 in the nucleus of CNC-derived palatal mesenchymal cells (Figure 5A-D). Furthermore, immunoblotting revealed that the level of H3K27me3 was increased in the palatal region of *Kdm6b* mutant mice (Figure 5E). Since the level of H3K27me3 can also be modified by the methyltransferases *Ezh1* and *Ezh2*, we further evaluated whether expression of *Ezh1* and *Ezh2* was affected in the palatal region. We found no obvious differences in either the distribution of *Ezh1*+ cells or the *Ezh1* protein level between control and *Kdm6b* mutant mice (Figure 5F-J). Similarly, no dramatic changes were observed in either the distribution of *Ezh2*+ cells or the *Ezh2* protein level between control and *Kdm6b* mutant mice (Figure 5K-O). These results indicated that

increased H3K27me3 in *Wnt1-Cre;Kdm6b^{fl/fl}* mice was mainly caused by loss of *Kdm6b* in CNC-derived cells. However, we did notice a broader contribution and stronger signal of Ezh2 than Ezh1 in the CNC-derived palatal mesenchyme. To investigate whether an increase of H3K27me3 in the CNC-derived cells caused the cleft phenotype we observed in *Wnt1-Cre;Kdm6b^{fl/fl}* mice, we generated *Wnt1-Cre;Kdm6b^{fl/fl};Ezh2^{fl/+}* mice and assessed the level of H3K27me3 in this model. In *Wnt1-Cre;Kdm6b^{fl/fl};Ezh2^{fl/+}* mice, we observed a rescue of the abnormal accumulation of H3K27me3 (Figure 5P-V). More importantly, haploinsufficiency of *Ezh2* in this model successfully rescued the cleft palate phenotype observed in *Wnt1-Cre;Kdm6b^{fl/fl}* mice (Figure 6A-O) with 70% efficiency (N = 10). CT scanning showed that both the palatine processes of the maxilla and palatine bone were restored in the *Wnt1-Cre;Kdm6b^{fl/fl};Ezh2^{fl/+}* mice (Figure 6A-C). Both bone and palatal mesenchymal tissue were rescued in *Wnt1-Cre;Kdm6b^{fl/fl};Ezh2^{fl/+}* mice (Figure 6D-O). These results suggested that an antagonistic interaction between the histone demethylase *Kdm6b* and methyltransferase *Ezh2* that modulates H3K27me3 is essential for palatogenesis.

Figure 5. Level of H3K27me3 is precisely regulated by *Kdm6b* and *Ezh2* during palatogenesis

(A-E) Contribution of H3K27me3 in the palatal shelf is evaluated using immunostaining and western blot at E13.5. Dotted lines in A and C indicate palatal shelf region. B and D are magnified images of boxes in A and C. Asterisk in B indicates no accumulation of H3K27me3 observed in control mice. Arrowheads in D indicate accumulation of H3K27me3 observed in *Wnt1-Cre;Kdm6b^{fl/fl}* mice. Scale bar: 50 μ m. (F-J) Contribution of *Ezh1* in the palatal shelf is evaluated using RNAscope *in situ* hybridization and western

342 blot at E13.5. Dotted lines in F and H indicate palatal shelf region. G and I are magnified images of boxes
 343 in F and H. Arrowheads in G and I indicate representative *Ezh1*⁺ cells. Scale bar: 50 μm.(K-O)
 344 Contribution of *Ezh2* in the palatal shelf is evaluated using immunostaining and western blot at E13.5.
 345 Dotted lines in K and M indicate palatal shelf region. L and N are magnified images of boxes in K and M.
 346 Arrowheads in L and N indicate representative *Ezh2*⁺ cells. Scale bar: 50 μm. (P-V) Contribution of
 347 H3K27me3 in the palatal shelf of control mice, *Kdm6b* mutant mice and *Ezh2* haploinsufficient model is
 348 evaluated using immunostaining and western blot at E13.5. Dotted lines in P, R, and T indicate palatal
 349 shelf region. Q, S, and U are magnified images of boxes in P, R, and T, respectively. Asterisks in Q and
 350 U indicate no accumulation of H3K27me3 observed in control (Q) and *Wnt1-Cre;Kdm6b^{fl/fl};Ezh2^{fl/+}* mice
 351 (U). White arrowheads in S indicate accumulation of H3K27me3 observed in *Wnt1-Cre;Kdm6b^{fl/fl}* mice.
 352 Scale bar: 50 μm.

353 Figure 5-source data 1 for figure 5E

354 Figure 5-source data 2 for figure 5E

355 Figure 5-source data 3 for figure 5E

356 Figure 5-source data 4 for figure 5E

357 Figure 5-source data 5 for figure 5J

358 Figure 5-source data 6 for figure 5J

359 Figure 5-source data 7 for figure 5J

360 Figure 5-source data 8 for figure 5O

361 Figure 5-source data 9 for figure 5O

362 Figure 5-source data 10 for figure 5O

363 Figure 5-source data 11 for figure 5V

364 Figure 5-source data 12 for figure 5V

365 Figure 5-source data 13 for figure 5V

366 Figure 5-source data 14 for figure 5V

367

368

369

Figure 6. Haploinsufficiency of *Ezh2* in *Wnt1-Cre;Kdm6b^{fl/fl};Ezh2^{fl/+}* mice rescues cleft palate

(A-C) CT images at PN0.5. White arrowheads in A and C indicate palatine process of maxilla observed in control and *Wnt1-Cre;Kdm6b^{fl/fl};Ezh2^{fl/+}* rescue model. Red arrows in A and C indicate palatine bone observed in control and *Wnt1-Cre;Kdm6b^{fl/fl};Ezh2^{fl/+}* rescue model. White asterisk in B indicates missing palate palatine process of maxilla in *Wnt1-Cre;Kdm6b^{fl/fl}* mice and red asterisk indicates missing palatine bone in *Kdm6b* mutant mice. Scale bar: 0.4 mm. (D-F) Coronal views of CT images at PN0.5. Asterisk in E indicates cleft palate observed in *Wnt1-Cre;Kdm6b^{fl/fl}* mice. Scale bar: 0.3 mm. (G-I) Whole-mount oral view at PN0.5. Arrowhead in H shows complete cleft palate observed in *Wnt1-Cre;Kdm6b^{fl/fl}* mice. Dashed lines in G-I indicate location of sections in J-O. Scale bar: 2 mm. (J-O) Histological analysis of samples at PN0.5. Asterisk in K and N indicates cleft palate in *Wnt1-Cre;Kdm6b^{fl/fl}* mice. M-O are magnified images of boxes in J-L, respectively. Dotted lines in M-O outline the bone structure. Scale bar: 200 μ m. Mes: mesenchyme; PPM: palatine process of maxilla.

***Kdm6b* activates expression of *p53* through removing H3K27me3 at the promoter of *p53* and providing chromatin accessibility to transcription factor Tfdp1**

Chromatin accessibility represents the degree to which chromatinized DNA is able to physically interact with nuclear macromolecules such as transcription factors for gene regulation (Klemm et al. 2019). The repressive mark H3K27me3 is usually associated with facultative heterochromatin and results in transcriptional repression due to decreased chromatin accessibility (Wiles and Selker 2017; Moller et al. 2019; den Broeder et al. 2020). Methyltransferase *Ezh2* and demethylase *Kdm6a/Kdm6b* can both regulate the methylation status of H3K27 to affect gene expression (Pediconi et al. 2019). To test whether *Kdm6b* and *Ezh2* can regulate expression of *p53* via H3K27me3, we first examined whether deposition of H3K27me3 changes at the promoter of *p53* in our models using ChIP-qPCR. A primer set was designed

at 1127 bp upstream of *p53* exon1 and the results showed that deposition of H3K27me3 significantly increased at the promoter of *p53* in the palatal region of *Kdm6b* mutant mice, while this increase was dampened in the *Ezh2* haploinsufficiency model (Figure 7A). Meanwhile, haplosufficiency of *Ezh2* in *Wnt1-Cre;Kdm6b^{fl/fl};Ezh2^{fl/+}* mice was able to restore the decreased expression of *p53* observed in the CNC-derived palatal mesenchyme of *Wnt1-Cre;Kdm6b^{fl/fl}* mice (Figure 7B-H). These data suggested that *Kdm6b* and *Ezh2* co-regulate expression of *p53* through H3K27me3.

As a H3K27me3 demethylase, *Kdm6b* is important for the regulation of chromatin structure for gene expression. To target a specific sequence in genome, a histone demethylase needs to interact with DNA binding proteins such as transcription factors or lncRNAs (Dimitrova et al. 2015; Gurrion et al. 2017). To identify a transcription factor that can interact with *Kdm6b*, we performed ATAC-seq analysis of palate tissue at E13.5. Through motif analysis we found that the promoter region of *p53* was accessible to members of the E2f transcription factor family (E2f4 and E2f6) and transcription factor *Tfdp1* (also known as *Dp1*), a binding partner of E2f family members (Figure 7I and Figure 7-figure supplement 6A). Previous research reported that inactivation of E2fs resulted in milder phenotypes than those associated with loss of *Tfdp1*, which leads to early embryonic lethality (Kohn et al. 2003). This result suggested that *Tfdp1* may play a more critical role than E2fs during embryonic development. A motif of *Tfdp1* was detected 1011 bp upstream of *p53* exon 1, which is very close to the H3K27me3 deposition site, by ATAC-seq analysis. ChIP-qPCR using palate tissue at E13.5 also revealed that binding of *Tfdp1* to the promoter region of *p53* decreased in the *Kdm6b* mutant mice (Figure 7J). Immunohistochemistry analysis showed that *Tfdp1*⁺ cells were distributed in the palatal region and co-expressed with *p53* and *Kdm6b* (Figure 7K-L). We also confirmed co-expression of *p53* and *Tfdp1* in the palatal region using our previously published scRNA-seq data (Figure 7-figure supplement 6B) (Han et al. 2021). Meanwhile, expression level and distribution of *Tfdp1* was not affected in the palatal mesenchyme in *Wnt1-Cre;Kdm6b^{fl/fl}* mice (Figure 7M

and Figure 7-figure supplement 6C-D). These data indicated that *Tfdp1* is not a downstream target of *Kdm6b*. To further test whether *Tfdp1* regulated expression of *p53* in the palatal mesenchymal cells, we transfected palatal mesenchymal cells from control mice at E13.5 using siRNA to knock down *Tfdp1*. qPCR revealed that the expression of *p53* was decreased in cells treated with siRNA for *Tfdp1* (Figure 7-figure supplement 6E and Figure 7N). This data further indicated that *p53* is a direct downstream target of *Tfdp1*.

To reveal the function of *Kdm6b-Tfdp1* interaction in the regulation of *p53* during palatogenesis, we transfected palatal mesenchymal cells with *Tfdp1*-overexpressing plasmid and found that expression of *p53* increased in the cells from control mice but not in the cells from *Wnt1-Cre;Kdm6b^{fl/fl}* mice (Figure 7-figure supplement 6F-G and Figure 7O-P). This result suggested that *Kdm6b* plays an essential role in activation of *p53* through interaction with *Tfdp1* during palatogenesis. To further test whether *Kdm6b* and *Tfdp1* are present in a same complex, we performed Co-IP experiments and found that these two proteins were indeed involved in the same complex (Figure 7Q). Collectively, these data suggested that *Kdm6b* and *Tfdp1* work together to activate *p53* expression in the palatal mesenchyme and play an important role in regulating palatogenesis (Figure 8).

Figure 7. *Kdm6b* regulates expression of *p53* through H3K27me3 and coordinates with transcription factor Tfdp1 in activation of *p53*

(A) ChIP-qPCR shows H3K27me3 deposition at the promoter region of *p53* in palatal tissues of control, *Kdm6b* mutant, and *Ezh2* haploinsufficient mice. ANOVA is used for statistical analysis. Asterisk indicates P < 0.05. (B-G) Expression of *p53* in palatal region at E13.5 using RNAscope *in situ* hybridization. Dotted lines in B, C and D indicate palatal shelf. E, F, and G are magnified images of boxes

in B, C, and D, respectively. Asterisk in F indicates decreased expression of p53 observed in *Wnt1-Cre;Kdm6b^{fl/fl}* mice. Scale bar: 50 μ m. (H) RT-qPCR analysis of *p53* expression in the palatal region of control, *Kdm6b* mutant and *Ezh2* haploinsufficient mice. ANOVA is used for statistical analysis. Asterisk indicates $P < 0.05$. (I) ATAC-seq analysis indicates that promoter region of *p53* is accessible for transcription factor TFDP1.(J) ChIP-qPCR using palatal tissue shows that binding of Tfdp1 to the promoter of *p53* decreases in the *Kdm6b* mutant mice. (K-L) Co-localization of Tfdp1, *Kdm6b* and *p53* at E13.5 using immunostaining and RNAscope *in situ* hybridization. Dotted lines in K indicate palatal shelf. L is a magnified image of the boxe in K. Arrowheads in L indicate representative cells that are positive for Tfdp1, *Kdm6b* and *p53*. Scale bar: 50 μ m in K and 5 μ m in L. (M) RT-qPCR quantification shows the expression of *Tfdp1* in samples collected at E13.5. N.S: not significant. (N) RT-qPCR analysis of *p53* expression in palatal mesenchymal cells after *Tfdp1* siRNA transfection. Asterisk indicates $P < 0.05$. (O-P) RT-qPCR analysis of *p53* expression in palatal mesenchymal cells transfected with *Tfdp1* overexpressing plasmid. Asterisk in O indicates $P < 0.05$. N.S: not significant. (Q) Co-IP experiment using protein extract from palatal tissues indicates that *Kdm6b* and Tfdp1 are presented in a same complex. Anti-Kdm6b antibody was used for immunoprecipitation. IgG served as negative control. IP: immunoprecipitation. IB: immunoblotting.

Figure 7-source data 1 for figure 7A

Figure 7-source data 2 for figure 7H

Figure 7-source data 3 for figure 7J

Figure 7-source data 4 for figure 7N

Figure 7-source data 5 for figure 7O

Figure 7-source data 6 for figure 7P

Figure 7-source data 7 for figure 7Q

461 Figure 7-source data 8 for figure 7Q
 462 Figure 7-source data 9 for figure 7Q
 463 Figure 7-source data 10 for figure 7Q
 464 Figure 7-source data 11 for figure 7Q
 465

466
 467 **Figure 8. Summary schematic drawing**

Discussion

The development of an organism from a single cell to multiple different cell types requires tightly regulated gene expression (Bruneau et al. 2019). Transcription factors, which are among the key regulators of this process, are intimately involved in cell fate commitment (Nelms and Labosky 2010; Soldatov et al. 2019). However, a transcription factor by itself cannot act on densely packed DNA in chromatin form. Thus, transcription factors must work in coordination with epigenetic regulatory mechanisms such as histone modifications, DNA methylation, chromatin remodeling and others to dynamically regulate chromatin states for gene expression (Wilson and Filipp 2018; Gokbuget and Blelloch 2019). Insights to the epigenetic landscape due to genetic, environmental or metabolic factors can lead to diverse developmental defects and diseases (Hobbs et al. 2014; Zoghbi and Beaudet 2016; Flavahan et al. 2017). Cleft palate comprises 30% of orofacial clefts, and can result from genetic mutations, environmental effects, or a combination thereof (Seelan et al. 2012). Much progress has been made in taking inventory of the gene mutations associated with craniofacial defects in recent years, and growing evidence has shown that epigenetic regulation plays an important role during neural crest development. For example, haploinsufficiency of *KDM6A* in humans causes severe psychomotor developmental delay, global growth restriction, seizures and cleft palate (Lindgren et al. 2013). Furthermore, studies have shown that *Kdm6a* and *Arid1a* are both indispensable during neural crest development (Chandler and Magnuson 2016; Shpargel et al. 2017). DNA methyltransferase3A (DNMT3A) plays a critical role in mediating the transition from neural tube to neural crest fate (Hu et al. 2012). Meanwhile, loss of *Ezh2*, a component of PRC2, in CNC-derived cells completely prevents craniofacial bone and cartilage formation (Schwarz et al. 2014). These studies have clearly shown that epigenetic regulation is crucial for neural crest development. In this study, we further demonstrate the important role of epigenetic regulation during the neural crest contribution to palate development using *Wnt1-Cre;Kdm6b^{fl/fl}* mice as a model. We show that

491 the demethylase *Kdm6b* is not only required for normal CNC-derived palatal mesenchymal cell
492 proliferation, but also for maintaining cell differentiation.

493 Epigenetic regulators, transcription factors, and lineage-specific genes work together to achieve
494 spatiotemporally restricted, tissue-specific regulation (Hu et al. 2014). In this study, we reveal that *Kdm6b*
495 works with the transcription factor *Tfdp1* to specifically regulate the expression of *p53*. The molecular
496 mechanisms underlying the function of *p53* in genomic stability and tumor suppression have been studied
497 extensively. However, the role of *p53* in regulating the development of CNC-derived cells still remains
498 largely unclear, although several studies have been conducted recently on certain aspects of this topic. For
499 instance, it has been shown that *p53* is able to coordinate CNC cell growth and epithelial-mesenchymal
500 transition/delamination processes by modulating cell cycle genes and proliferation (Rinon et al. 2011). It
501 has also been established that both deletion and overexpression of *p53* result in craniofacial defects
502 (Tateossian et al. 2015; Bowen et al. 2019). Furthermore, nuclear stabilization of p53 protein in *Tcof*^{+/+}
503 mice induces neural crest cell progenitors to undergo cell-cycle arrest and caspase3-mediated apoptosis in
504 the neuroepithelium. Inhibition of p53 function successfully rescues the neurocristopathy in an animal
505 model of Treacher Collins syndrome, which results from mutation in *Tcof1* (Jones et al. 2008). These
506 studies have clearly shown that appropriate function of *p53* is indispensable in CNCCs. However, none
507 of these studies have addressed upstream regulation of *p53* in CNCCs.

508 Here, we show that proper function of *p53* during the differentiation and proliferation of CNCCs is
509 orchestrated by *Kdm6b* and *Ezh2* through H3K27me3. Altering the balance between *Ezh2* and *Kdm6b* can
510 cause abnormal H3K27me3 function, which further affects the downstream transcription factor *p53*. In
511 addition, we have detected spontaneous DNA damage in the developing palate and increased
512 accumulation of DNA damage in the *Wnt1-Cre;Kdm6b*^{fl/fl} mice. These findings further demonstrate the
513 critical function of *p53* in protecting embryonic cells from DNA damage during development.

Furthermore, the ability of cells to proliferate is limited by the length of the telomeres, which gradually shorten during each cell replication (Blagoev 2009). Once the telomeres are too short for DNA replication, the result is cellular senescence, which induces an irreversible inability to proliferate (Bernadotte et al. 2016). In this study we notice that downregulated expression of *p53* in *Wnt1-Cre;Kdm6b^{fl/fl}* mice results in hyperproliferation and increased DNA damage in the proliferative cells, which might further leads to cell senescence.

Previous research has shown that KDM3A functions as a cofactor of STAT3 to activate the JAK2-STAT3 signaling pathway (Kim et al. 2018) and that KDM2A coordinates with c-Fos in regulating *COX-2* (Lu et al. 2015). Our study shows that Kdm6b coordinates with the transcription factor Tfdp1 to activate expression of *p53* in CNCCs, and that *Ezh2* and *Kdm6b* co-regulate H3K27 methylation status, which may affect the ability of Tfdp1 to bind to the chromatin during palatogenesis. It has been reported that *Tfdp1* is crucial for embryonic development and for regulating Wnt/ β -catenin signaling (Kohn et al. 2003; Kim et al. 2012). Interaction between Kdm6b and Tfdp1 discovered in this study further increases our knowledge of the coordination between epigenetic regulators and transcription factors during organogenesis. As environmental insults can adversely affect the function of epigenetic regulators, our findings provide a better understanding of the epigenetic regulation and transcription factors involved in regulating the fate of CNC cells and craniofacial development, which can provide important clues about human development, as well as potential therapeutic approaches for craniofacial birth defects.

534 **Materials and Methods**

535 **Animals**

536 To generate *Wnt1-Cre;Kdm6b^{fl/fl}* mice, we crossed *Wnt1-Cre;Kdm6b^{fl/+}* mice with *Kdm6b^{fl/fl}* mice (Zhao
537 et al. 2008; Manna et al. 2015). Reporter mice used in this study were tdTomato conditional reporter
538 (JAX#007905) (Madisen et al. 2010). *Ezh2^{fl/fl}* and *p53^{fl/fl}* mice were purchased from Jackson Laboratory
539 (JAX#022616, #008462) (Marino et al. 2000; Shen et al. 2008). Genotyping was carried out as previously
540 described (Zhao et al. 2008). Briefly, tail samples were lysed by using DirectPCR tail solution (Viagen
541 102 T) with overnight incubation at 55°C. After heat inactivation at 85°C for 1 hour, PCR-based
542 genotyping (GoTaq Green MasterMix, Promega, and C1000 Touch Cyclers, Bio-rad) was used to detect
543 the genes. All mouse studies were conducted with protocols approved by the Department of Animal
544 Resources and the Institutional Animal Care and Use Committee (IACUC) of the University of Southern
545 California (Protocols 9320 and 20299).

546 **MicroCT analysis**

547 MicroCT was used to analyze the control, *Kdm6b*, and other mutant samples. Mouse samples were
548 dissected and fixed in 4% paraformaldehyde overnight at 4°C followed by CT scanning (Scanco Medical
549 μ CT50 scanner) at the University of Southern California Molecular Imaging Center as previously
550 described (Grosshans et al. 2006; Sugii et al. 2017). AVIZO 9.1.0 (Visualization Sciences Group) was
551 used for visualization and 3D microCT reconstruction.

552 **Alcian blue-Alizarin red staining**

553 Mouse heads were dissected and fixed in 95% EtOH overnight at room temperature. Staining was
554 performed as previously described (Rigueur and Lyons 2014). Briefly, 95% EtOH was replaced with 100%

555 acetone for 2 days and then samples were incubated in Alcian blue solution (80% EtOH, 20% glacial
556 acetic acid, and 0.03% (w/v) Alcian blue 8GX (Sigma, A3157) for 1-3 days. Samples were then destained
557 with 70% EtOH and incubated in 95% EtOH overnight. After incubation, samples were pre-cleared with
558 1% KOH and then incubated in Alizarin red solution (0.005% (w/v) Alizarin red (Sigma, A5533) in 1%
559 (w/v) KOH) for 2-5 days. After clearing samples with 1% KOH, they were stored in 100% glycerol until
560 analysis.

561 **Sample preparation for sectioning**

562 Samples for paraffin sectioning were prepared using the standard protocol in our laboratory. Briefly,
563 samples were fixed in 4% PFA and decalcified with 10% EDTA as needed. Then, samples were
564 dehydrated with serial ethanol solutions (50%, 70%, 80%, 90% and 100%) at room temperature followed
565 by xylene and then embedded in paraffin wax. Sections were cut to 6 μ m on a microtome (Leica) and
566 mounted on SuperFrost Plus slides (Fisher, 48311-703). Cryosectioning samples were fixed and
567 decalcified the same way as samples prepared for paraffin sectioning. Sucrose (15% and 30%) was used
568 to remove water from the samples before embedding them in OCT compound (Tissue-Tek, 4583).
569 Cryosections were cut to 8 μ m on a cryostat (Leica) and mounted on SuperFrost Plus slides (Fisher).

570 **Histological analysis**

571 Paraffin sections prepared as described above were used for histological analysis. Hematoxylin and Eosin
572 staining were performed using the standard protocol (Cardiff et al. 2014).

573 **Immunofluorescence assay**

574 Cryosections and paraffin sections prepared as described above were used for immunofluorescence assays.
575 Sections were dried for 2 hours at 55°C. Paraffin sections were deparaffinized and rehydrated before
576 antigen retrieval. Heat mediated antigen retrieval was used to process sections (Vector, H-3300) and then

samples were blocked for 1 hour in blocking buffer at room temperature (PerkinElmer, FP1020). Primary antibodies diluted in blocking buffer were incubated with samples overnight at 4°C. After washing with PBST (0.1% Tween20 in 1xPBS), samples were then incubated with secondary antibodies at room temperature for 2 hours. DAPI (Sigma, D9542) was used for nuclear staining. All images were acquired using Leica DMI 3000B and Keyence BZ-X710/810 microscopes. Detailed information about primary and secondary antibodies is listed in Table S1.

EdU labeling

EdU solution was prepared at 10 mg/mL in PBS, and then pregnant mice at the desired stage were given an intra-peritoneal injection (IP) based on their weight (0.1 mg of EdU/1 g of mouse). Embryos were collected after 2 hours or 48 hours and then prepared for sectioning as above. EdU signal was detected using Click-It EdU cell proliferation kit (Invitrogen, C10337) and images were acquired using Leica DMI 3000B and Keyence BZ-X710/810 microscopes.

TUNEL staining

Cryosections and paraffin sections were prepared as described above, and cell death was analyzed using TUNEL staining according to the manufacturer's protocol (Invitrogen, C10245). Images were acquired using Keyence BZ-X710/810 microscope.

RNAscope *in situ* hybridization

RNAscope *in situ* hybridization in this study was performed on cryosections using RNAscope 2.5HD Reagent Kit-RED assay (Advanced Cell Diagnostics, 322350) and RNAscope multiplex fluorescent v2 assay (Advanced Cell Diagnostics, 323100) according to the manufacturer's protocol. RNAscope probes used in this study included *Kdm6a*, *Kdm6b*, *Uty*, and *p53*. Detailed information about probes is listed in Table S2.

599 RNA-sequencing and analysis

600 Palate samples from control and *Wnt1-Cre;Kdm6b^{fl/fl}* mice were collected at E12.5 for RNA isolation with
 601 RNeasy Micro Kit (Qiagen) according to the manufacturer's protocol. The quality of RNA samples was
 602 determined using an Agilent 2100 Bioanalyzer and all samples for sequencing had RNA integrity (RIN)
 603 numbers > 9. cDNA library preparation and sequencing were performed at the USC Molecular Genomics
 604 Core. Single-end reads with 75 cycles were performed on Illumina Hiseq 4000 equipment and raw reads
 605 were trimmed and aligned using TopHat (Version 2.0.8) with the mm10 genome. CPM was used to
 606 normalize the data and differential expression was calculated by selecting transcripts that changed with p
 607 < 0.05.

608 RNA extraction and real-time qPCR

609 Palatal tissue used for RNA isolation was dissected at desired stages and an RNeasy Plus Micro Kit
 610 (Qiagen, 74034) was used to isolate the total RNA followed by cDNA synthesis using an iScript cDNA
 611 synthesis kit (Bio-Rad, 1708891). Real-time qPCR quantification was done on a Bio-Rad CFX96 Real-
 612 Time system using SsoFast EvaGreen Supermix (Bio-Rad, 1725201). Detailed information on primers is
 613 listed in Table S3.

614 ChIP-qPCR

615 Palate tissue was dissected from control and *Wnt1-Cre;Kdm6b^{fl/fl}* mice at E13.5. Each replicate contained
 616 60-80 mg tissue combined from multiple animals. Samples were prepared following the manufacturer's
 617 protocol (Chromatrap, 500191). Briefly, tissue was cut into small pieces and then fixed with 1%
 618 formaldehyde at room temperature for 15 minutes, followed by incubating with 0.65 M glycine solution.
 619 Then the sample was washed twice with PBS, resuspended in Hypotonic Buffer and incubated at 4°C for
 620 10 minutes to obtain nuclei, which were then resuspended in Digestion Buffer. After chromatin was

sheared to 100-500 bp fragments using Shearing Cocktail, 10 µg chromatin with H3K27me3 antibody (CST 9733s, 1:50), DP1 antibody (Abcam ab124678, 1:10) or Immunoglobulin G negative control (2 µg) was added to Column Conditioning Buffer to make up the final volume of 1000 µl. Immunoprecipitation (IP) slurry was mixed thoroughly and incubated on an end-to-end rotor for 1 hour at 4 °C. An equivalent amount of chromatin was set as an input. After 1 hour incubation, IP slurry was purified using Chromatrap® spin column at room temperature and chromatin was eluted using ChIP-seq elution buffer. Chromatin sample and input were further incubated at 65 °C overnight to reverse cross-linking. DNA was purified with Chromatrap® DNA purification column after proteinase K treatment. ChIP eluates, negative control and input were assayed using real-time qPCR. Primers were designed using the promoter region of *p53*. Detailed information is available in Table S3.

Western blot and Co-Immunoprecipitation

For western blot, palate tissue was dissected from control and *Wnt1-Cre;Kdm6b^{fl/fl}* mice at E13.5. The tissue sample was lysed using RIPA buffer (Cell Signaling, 9806) with protease inhibitor (Thermo Fisher Scientific, A32929) for 20 minutes on ice followed by centrifugation at 4°C to remove tissue debris. Protein extracts were then mixed with sample buffer (Bio-Rad, 1610747) and boiled at 98°C for 10 minutes. Then denatured protein extract was separated in 4%-15% precast polyacrylamide gel (Bio-Rad, 456-1084) and then transferred to 0.45µm PVDF membrane. Transferred membrane was incubated with 5% milk for 1 hour at room temperature, and incubated with primary antibody (Table S4) at 4°C overnight. After washing with TBST, membrane was incubated with secondary antibody for 2 hours at room temperature and signals were detected using SuperSignal West Femto (Thermo Fisher Scientific, 34094) and Azure 300 (Azure Biosystems).

For CoIP, palate tissue was dissected from control mice at E13.5 and 60-80 mg tissue was combined as one sample for each replicate. After lysing using RIPA buffer, 60 µl of the protein extract was mixed with

sample buffer and boiled at 98 °C to serve as input. The remaining protein extract was incubated with primary antibody at 4 °C overnight. Protein G beads from GE Healthcare (GE Healthcare, 10280243) were used to purify the target protein and then the protein sample was analyzed using western blot. Detailed information about primary and secondary antibodies is listed in Table S4.

siRNA and plasmid transfection

Palatal tissue was dissected from control and *Wnt1-Cre;Kdm6b^{fl/fl}* mice at E13.5, then cut into small pieces using a scalpel. This minced tissue was then cultured in DMEM medium (Gibco, 2192449) containing 40% MSC FBS (Gibco, 2226685P) and 1% Pen Strep (Gibco, 2145477) at 37°C.

siRNA (Qiagen) and plasmid (OriGene) transfection was performed following the manufacturer's protocol (Qiagen, 301704 and OriGene, TF81001). Briefly, siRNA was transfected into cells in 24-well plates at 10nM for 3 days followed by qPCR and EdU proliferation assay. Plasmid was transfected into cells in 24-well plates using 1µg/µl stock solution for 2 days followed by real-time qPCR. Primers designed for qPCR are listed in Table S3. siRNA sequence and plasmid information are listed in Table S5 and Table S6.

ATAC-seq analysis

Palate tissue of E13.5 control mice was digested using TrypLE express enzyme (Thermo Fisher Scientific, 12605010) and incubated at 37 °C for 20 minutes with shaking at 600 rpm. Single-cell suspension was prepared according to the 10X Genomics sample preparation protocol and processed to generate ATAC-seq libraries according to a published protocol (Buenrostro et al. 2015). Sequencing was performed using the NextSeq 500 platform (Illumina) and ATAC-seq reads were aligned to the UCSC mm10 reference genome using BWA-MEN (Li 2013). Then ATAC-seq peaks were called by MACS2 and annotated.

Known transcription factor binding motifs were analyzed by HOMER (Zhang et al. 2008; Heinz et al. 2010).
Quality files for sequencing is listed in Table S7

Cell differentiation assay

Palatal tissue was dissected from control and *Wnt1-Cre;Kdm6b^{fl/fl}* mice at E13.5 and cultured as previously described. Then the differentiation assay was conducted according to the manufacturer's protocol (Gibco, A1007201). Briefly, mesenchymal cells were seeded into cell culture plates at the desired concentration followed by incubation at 36°C in a humidified atmosphere of 5% CO₂ for the required time (a minimum of 2 hours and up to 4 days). Then growth medium was replaced by complete differentiation medium and cells were continuously incubated for 3 weeks under osteogenic conditions. After specific periods of cultivation, cells were stained using 2% Alizarin Red S solution (PH 4.2) solution. Images were acquired using EPSON Scan and Keyence BZ-X710/810 microscopes. Quantification of the Alizarin Red S staining was conducted according to the manufacturer's protocol (ScienCell, 8678).

Nutlin-3 treatment

Nutlin-3 (Sigma, N6287) was dissolved in corn oil (Sigma, C8267) with 10% DMSO (Sigma, D2650) and given to pregnant mice on days 10.5, 12.5 and 14.5 of pregnancy at a dosage based on their weight (10 mg/kg) (Li et al. 2016). Then embryos were collected at E16.5 for analysis.

Statistics

Statistical analysis was completed using GraphPad Prism and significance was assessed by independent two-tailed Student's t-test or ANOVA. The chosen level of significance for all statistical tests in this study was $p < 0.05$. Data is presented as mean $\pm$ SEM. N=3 samples were analyzed for each experimental group unless otherwise stated.

686 **Acknowledgements**

687 We thank Bridget Samuels and Linda Hattemer for critical reading of the manuscript and also
688 acknowledge USC Libraries Bioinformatics Service for their assisting with data analysis. Meanwhile, we
689 thank USC Office of Research and the Norris Medical Library for the bioinformatics software and
690 computing resources. Furthermore, we appreciate the funding support from the National Institute of Dental
691 and Craniofacial Research, National Institutes of Health (R01 DE012711, R01 DE022503, and U01
692 DE028729 to Yang Chai).

693 **Author contributions**

694 T.G. and Y.C. designed the study. T.G. carried out most of the experiments, generated all figures and
695 analyzed the data. X.H., J.H., J.F., and J.J. participated in the sample collection and data analysis. E.J.,
696 and J.L. provided critical comments for this manuscript. T-V.H. participated in the microCT analysis.
697 J.X. provided critical suggestion for the manuscript. T.G. and Y.C. co-wrote the paper. Y.C. supervised
698 the research.

699 **Competing interests**

700 The authors have declared that no conflict of interest exists.

Supplementary figures

Figure 1-figure supplement 1. Expression of Kdm6 family

704 (A-L) Expression of Kdm6 family genes in the palatal region at E13.5 using RNAscope *in situ* hybridization. D,
705 E, F, J, K, and L are magnified images of boxes in A, B, C, G, H, and I respectively. Dotted lines in A, B, C, G,
706 H, and I indicate region of palatal shelf. Dotted lines in D, E, F, J, K, and L indicate epithelium. Schematic
707 drawing at bottom of the figure indicates the location of the presented section. Scale bar: 50 μ m. PS: palatal shelf;
708 Mes: mesenchyme; Epi: epithelium. (M-N) Protein quantification of Kdm6a and Kdm6b in control and *Kdm6b*
709 mutant palatal region at E13.5 using western blot. (O-P) Expression of *Kdm6b* in the first pharyngeal arch at E9.5
710 assessed using RNAscope *in situ* hybridization. Arrows in P indicate expression of *Kdm6b* at epithelium. PA1:
711 first pharyngeal arch. Scale bar: 50 μ m.

712 Figure supplement 1-source data 1 for figure supplement 1M

713 Figure supplement 1-source data 2 for figure supplement 1M

714 Figure supplement 1-source data 3 for figure supplement 1M

715 Figure supplement 1-source data 4 for figure supplement 1N

716 Figure supplement 1-source data 5 for figure supplement 1N

717 Figure supplement 1-source data 6 for figure supplement 1N

Figure 1-figure supplement 2. Loss of *Kdm6b* in epithelium and CNC-derived cells

(A-C and E-G) CT images and histological analysis of *K14-Cre;Kdm6b^{fl/fl}* mice at PN0.5. Scale bars in A and E: 0.4 mm; Scale bars in B and F: 0.6 mm; Scale bars in C and G: 100 μ m. (D and H) Expression of *Kdm6b* assessed using RNAscope *in situ* hybridization at E13.5. *Kdm6b* is efficiently knocked out from epithelium in *K14-Cre;Kdm6b^{fl/fl}* mice. Dotted lines in D and H indicate epithelium. Scale bar: 100 μ m. Epi: epithelium; DE: dental epithelium. (I-N) No obvious phenotype was observed in skull bones or mandible in *Wnt1-Cre;Kdm6b^{fl/fl}* mice at PN0.5. Yellow triangles in J and M indicate location of palatine process of maxilla and red triangle indicates

726 location of palatine bone. Arrowhead in N indicates flatten skull observed in *Wnt1-Cre;Kdm6b^{fl/fl}* mice. Scale bar
 727 in I and L: 0.6 mm; Scale bar in J and M: 1 mm.

728

729

730

731

732

733

Figure 1-figure supplement 3. Loss of *Kdm6b* in CNC-derived cells results in soft palate muscle defects

(A-P) Histological analysis of soft palate muscles at PN0.5. Boxes in A, B, C, D, I, J, K, and L are shown magnified in E, F, G, H, M, N, O, and P, respectively. Dotted lines outline each muscle. Asterisks in I, J, K, and L indicate cleft palate observed in *Wnt1-Cre;Kdm6b^{fl/fl}* mice. PP: pterygoid plate; PLG: palatoglossus; TVP: tensor veli palatini; LVP: levator veli palatini; PLP: palatopharyngeus. Scale bar: 100 μ m. Asterisks in I-L indicate cleft in *Wnt1-Cre;Kdm6b^{fl/fl}* mice. (Q-X) Immunostaining of MHC at PN0.5. Dotted lines outline each

741 muscle. PLG: palatoglossus; TVP: tensor veli palatini; LVP: levator veli palatini; PLP: palatopharyngeus. Scale

742 bar: 50 μ m.

743

744

745

746

747

748

Figure 2-figure supplement 4. *Kdm6b* is not required for CNCCs to populate pharyngeal arches but is critical for survival of palatal mesenchymal cells

(A-B) Whole-mount images of tdTomato reporter mice at E10.5. Arrowheads indicate CNCCs that have successfully migrated to the pharyngeal arch at E10.5. No differences were observed between control and *Wnt1-Cre;Kdm6b^{fl/fl}* mutant mice. Insets show immunostaining of tdTomato at E10.5. Dotted lines in the insets indicate first pharyngeal arch. PA1: first pharyngeal arch. Scale bars: 1 mm. (C-D) Histological analysis of samples at E14.5. Asterisk in D indicates cleft palate observed in *Wnt1-Cre;Kdm6b^{fl/fl}* mice. PS: palatal shelf. Scale bar: 100 μ m. (E-H) TUNEL staining at E13.5 and E14. Dotted lines indicate palatal shelves. Arrows in E, F and H indicate cells with positive TUNEL staining. Scale bar: 50 μ m.

Figure 4-figure supplement 5. *p53* plays a critical role in regulating palatogenesis

(A-C) RT-qPCR analysis of *p53*, *Runx2* and *Sp7* expression in cells isolated from palatal region of control mice 3 days after transfection with *p53* siRNA. Asterisk indicates $P < 0.05$. (D-E) Histological analysis of samples treated with 10% DMSO in corn oil at E10.5, E12.5 and E14.5. Asterisk in E indicates cleft palate observed in *Wnt1-Cre;Kdm6b^{fl/fl}* mouse. Scale bar: 200 μ m. (F) p53 protein in the palatal region quantified using western blot.

Figure supplement 5-source data 1 for figure supplement 5A

Figure supplement 5-source data 2 for figure supplement 5B

Figure supplement 5-source data 3 for figure supplement 5C

Figure supplement 5-source data 4 for figure supplement 5F

Figure supplement 5-source data 5 for figure supplement 5F

Figure supplement 5-source data 6 for figure supplement 5F

Figure supplement 5-source data 7 for figure supplement 5F

Figure supplement 5-source data 8 for figure supplement 5F

Figure 7-figure supplement 6. Kdm6b and transcription factors are involved in regulating *p53*

(A) ATAC-seq analysis suggests that the promoter of *p53* is accessible to transcription factors E2f4 and E2f6. (B) Co-expression of *p53* and *Tfdp1* in the palatal region at E13.5 using published scRNA-seq analysis (GEO: GSE155928). (C-D) Immunostaining of Tfdp1 in the palatal region of control and *Kdm6b* mutant mice. Arrows indicate representative Tfdp1+ cells. Scale bar: 50 μ m. (E) RT-qPCR analysis of *Tfdp1* expression in cells isolated from palatal region of control mice 3 days after transfection with *Tfdp1* siRNA. Asterisk indicates $P < 0.05$. (F-

G) RT-qPCR analysis of *Tfdp1* expression in palatal mesenchymal cells isolated from control and *Kdm6b* mutant mice after transfection with *Tfdp1* overexpressing plasmid. F represents the result using cells isolated from control mice and G represents the result using cells isolated from *Wnt1-Cre;Kdm6b^{fl/fl}* mice. Asterisks indicate $P < 0.05$.

Figure supplement 6-source data 1 for figure supplement 6E

Figure supplement 6-source data 2 for figure supplement 6F

Figure supplement 6-source data 3 for figure supplement 6G

Supplementary Tables

Antibodies	Vendor	Cat No.	Dilution
myosin heavy chain (MHC)	DSHB	P13538	1:10
Histone H3 tri methyl K27 (H3K27me3)	Cell signaling	9733s	1:200
Phospho-Histone H2A.X (Ser139)	Cell signaling	9718s	1:200
Dp1	Abcam	ab124678	1:100
Ezh2	Cell Signaling	5246s	1:200
Alexa Fluor 568	Invitrogen	A-11011	1:200
Alexa Fluor 488	Invitrogen	A-32931	1:200

Table S1

Probes	Vendor	Cat No.
<i>Kdm6a</i>	Advanced Cell Diagnostics	456961
<i>Kdm6b</i>	Advanced Cell Diagnostics	477971
<i>Kdm6b-01</i>	Advanced Cell Diagnostics	501231
<i>Uty</i>	Advanced Cell Diagnostics	451741
<i>Trp53</i>	Advanced Cell Diagnostics	402331
<i>Trp53-C2</i>	Advanced Cell Diagnostics	402331-C2
<i>Ezh1</i>	Advanced Cell Diagnostics	895231

Table S2

Genes		Primer sequence
<i>p53</i> ChIP-qPCR	Forward	5'-AGGTCAGGAGGGAGGCTATC-3'
	Reverse	5'-GCTTTGGACACTCGTTCCT-3'
<i>p53</i> RT-qPCR	Forward	5'-GTGTGGTGCAGATCGCAGT-3'
	Reverse	5'-ATCATGCCTTCGGACTTGATG-3'
<i>Gapdh</i> RT-qPCR	Forward	5'-TGGATTTGGACGCATTGGTC-3'
	Reverse	5'-TTTGCACTGGTACGTGTTGAT-3'
<i>Tfdp1</i> RT-qPCR	Forward	5'-TTGAAGCCAACGGAGAACTAAAG-3'
	Reverse	5'-TGGACTGTCCGAAGGTTTTTG-3'
<i>Runx2</i> RT-qPCR	Forward	5'-AGAGTCAGATTACAGATCCCAGG-3'
	Reverse	5'-TGGCTCTTCTTACTGAGAGAGG-3'
<i>Sp7</i> RT-qPCR	Forward	5'-AAGTCTCAAGGTTATAGGGACGG-3'
	Reverse	5'-CCATGCTTGTCTGGGTATAGTGT-3'

Table S3

Antibodies	Vendor	Cat No.	Dilution
Histone H3 tri methyl K27 (H3K27me3)	Cell signaling	9733s	1:1000
Dp1	Abcam	ab124678	1:1000
Ezh1	Abcam	ab189833	1:1000
Ezh2	Cell Signaling	5246s	1:2000
Kdm6a	Abcam	ab36938	1:1000
Kdm6b (C-term)	Abcepta	AP1022b	1:1000
Kdm6b (N-term)	Abcepta	AP1022a	1:1000
p53	Santa Cruz	sc-126	1:1000
Histone H3	Cell signaling	4499s	1:1000
Beta Actin	Abcam	ab20272	1:2000
Rabbit IgG HRP-conjugated antibody	R&D System	HAF008	1:2000
Mouse IgG HRP-conjugated antibody	R&D System	HAF007	1:2000
HRP, Mouse Anti-Rabbit IgG LCS	IPKine™	A25022	1:2000

Table S4

Product name	Cat No.	Target sequence
Mm_Trp53_5	SI04394257	CTGGGACAGCCAAGTCTGTTA
Mm_Trp53_4	SI01456532	TGGAGAGTATTTCACCCTCAA
Mm_Trp53_3	SI01456525	ACCGCCGTACAGAAGAAGAAA
Mm_Trp53_1	SI01456511	CCGGGTGGAAGGAAATTTGTA
Mm_Tfdp1_7	SI02710834	CAGAATCTTAGTCCTGGGAAA
Mm_Tfdp1_6	SI02688840	AAAGGTCTTTATAGACCAGAA
Mm_Tfdp1_5	SI02668918	CACACCAGTGACAATGACAAA
Mm_Tfdp1_1	SI00183995	AACGACGAGGAGGATTGATTA
AllStars Negative Control siRNA	1027280	

Table S5

Product name	Vendor	Cat No.
pCMV6-AC-GFP, mammalian vector	OriGene	PS100010
Tfdp1 (NM_009361) Mouse Tagged ORF Clone	OriGene	MG221670
Turbo Fectin Transfection Reagent	OriGene	TF81001

Table S6

Pre-alignment qa/qc					
Sample name	Total reads	Read length	Avg. read quality	% N	% GC
6B-WT_S3	117089731	76	33.4671	0.046936	44.9143

Post-alignment qa/qc																		
Sample name	Total reads	Total alignments	Aligned	Total unaligned	Unaligned	Total unique singleton	Unique singleton	Total unique paired	Unique paired	Total non-unique paired	Non-unique paired	Total non-unique singleton	Non-unique singleton	Coverage	Avg. coverage depth	Avg. length	Avg. quality	%GC
6B-WT_S3	117089731	226531231	97.26489422	3202528	2.735106	1951709	1.666849	1.11E+08	94.96082	701598	0.599197	44522	0.038024	80.3266	7.09937	75.8895	33.6187	45.1441

Table S7

Source Data Files

Figure 2-Source data 1 for figure 2C

Figure 2-Source data 2 for figure 2H

Figure 2-source data 3 for figure 2U

Figure 3-Source data 1 for figure 3H

Figure 3-Source data 2 for figure 3M

Figure 3-Source data 3 for figure 3R

Figure 4-Source data 1 for figure 4C

Figure 4-Source data 2 for figure 4F

Figure 5-source data 1 for figure 5E

Figure 5-source data 2 for figure 5E

Figure 5-source data 3 for figure 5E

Figure 5-source data 4 for figure 5E

Figure 5-source data 5 for figure 5J

Figure 5-source data 6 for figure 5J

Figure 5-source data 7 for figure 5J

855 Figure 5-source data 8 for figure 5O

856 Figure 5-source data 9 for figure 5O

857 Figure 5-source data 10 for figure 5O

858 Figure 5-source data 11 for figure 5V

859 Figure 5-source data 12 for figure 5V

860 Figure 5-source data 13 for figure 5V

861 Figure 5-source data 14 for figure 5V

862 Figure 7-source data 1 for figure 7A

863 Figure 7-source data 2 for figure 7H

864 Figure 7-source data 3 for figure 7J

865 Figure 7-source data 4 for figure 7N

866 Figure 7-source data 5 for figure 7O

867 Figure 7-source data 6 for figure 7P

868 Figure 7-source data 7 for figure 7Q

869 Figure 7-source data 8 for figure 7Q

870 Figure 7-source data 9 for figure 7Q

871 Figure 7-source data 10 for figure 7Q

872 Figure 7-source data 11 for figure 7Q

873 Figure supplement 1-source data 1 for figure supplement 1M

874 Figure supplement 1-source data 2 for figure supplement 1M

875 Figure supplement 1-source data 3 for figure supplement 1M

876 Figure supplement 1-source data 4 for figure supplement 1N

877 Figure supplement 1-source data 5 for figure supplement 1N

878 Figure supplement 1-source data 6 for figure supplement 1N

879 Figure supplement 5-source data 1 for figure supplement 5A

880 Figure supplement 5-source data 2 for figure supplement 5B

881 Figure supplement 5-source data 3 for figure supplement 5C

882 Figure supplement 5-source data 4 for figure supplement 5F

883 Figure supplement 5-source data 5 for figure supplement 5F

884 Figure supplement 5-source data 6 for figure supplement 5F

885 Figure supplement 5-source data 7 for figure supplement 5F

886 Figure supplement 5-source data 8 for figure supplement 5F

887 Figure supplement 6-source data 1 for figure supplement 6E

888 Figure supplement 6-source data 2 for figure supplement 6F

889 Figure supplement 6-source data 3 for figure supplement 6G

890

891

892

893

894

895

896

References

- Arya AK, El-Fert A, Devling T, Eccles RM, Aslam MA, Rubbi CP, Vlatkovic N, Fenwick J, Lloyd BH, Sibson DR et al. 2010. Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53. *Br J Cancer* **103**: 186-195. <https://doi.org/10.1038/sj.bjc.6605739>
- Bannister AJ, Kouzarides T. 2011. Regulation of chromatin by histone modifications. *Cell Res* **21**: 381-395. <https://doi.org/10.1038/cr.2011.22>
- Bernadotte A, Mikhelson VM, Spivak IM. 2016. Markers of cellular senescence. Telomere shortening as a marker of cellular senescence. *Aging-Us* **8**: 3-11. <https://doi.org/10.18632/aging.100871>
- Blagoev KB. 2009. Cell proliferation in the presence of telomerase. *PLoS One* **4**: e4622. <https://doi.org/10.1371/journal.pone.0004622>
- Bowen ME, Attardi LD. 2019. The role of p53 in developmental syndromes. *J Mol Cell Biol* **11**: 200-211. <https://doi.org/10.1093/jmcb/mjy087>
- Bowen ME, McClendon J, Long HK, Sorayya A, Van Nostrand JL, Wysocka J, Attardi LD. 2019. The Spatiotemporal Pattern and Intensity of p53 Activation Dictates Phenotypic Diversity in p53-Driven Developmental Syndromes. *Dev Cell* **50**: 212-228 e216. <https://doi.org/10.1016/j.devcel.2019.05.015>
- Bruneau BG, Koseki H, Strome S, Torres-Padilla ME. 2019. Chromatin and epigenetics in development: a Special Issue. *Development* **146**. <https://doi.org/10.1242/dev.185025>
- Buenrostro JD, Wu B, Chang HY, Greenleaf WJ. 2015. ATAC-seq: A Method for Assaying Chromatin Accessibility Genome-Wide. *Curr Protoc Mol Biol* **109**: 21 29 21-21 29 29. <https://doi.org/10.1002/0471142727.mb2129s109>
- Bush JO, Jiang R. 2012. Palatogenesis: morphogenetic and molecular mechanisms of secondary palate development. *Development* **139**: 231-243. <https://doi.org/10.1242/dev.067082>
- Cardiff RD, Miller CH, Munn RJ. 2014. Manual hematoxylin and eosin staining of mouse tissue sections. *Cold Spring Harb Protoc* **2014**: 655-658. <https://doi.org/10.1101/pdb.prot073411>
- Chai Y, Maxson RE, Jr. 2006. Recent advances in craniofacial morphogenesis. *Dev Dyn* **235**: 2353-2375. <https://doi.org/10.1002/dvdy.20833>
- Chandler RL, Magnuson T. 2016. The SWI/SNF BAF-A complex is essential for neural crest development. *Dev Biol* **411**: 15-24. <https://doi.org/10.1016/j.ydbio.2016.01.015>
- Chandrasekharan D, Ramanathan A. 2014. Identification of a novel heterozygous truncation mutation in exon 1 of ARHGAP29 in an Indian subject with nonsyndromic cleft lip with cleft palate. *Eur J Dent* **8**: 528-532. <https://doi.org/10.4103/1305-7456.143637>
- Cobourne MT, Xavier GM, Depew M, Hagan L, Sealby J, Webster Z, Sharpe PT. 2009. Sonic hedgehog signalling inhibits palatogenesis and arrests tooth development in a mouse model of the nevoid basal cell carcinoma syndrome. *Dev Biol* **331**: 38-49. <https://doi.org/10.1016/j.ydbio.2009.04.021>
- Cordero DR, Brugmann S, Chu Y, Bajpai R, Jame M, Helms JA. 2011. Cranial neural crest cells on the move: their roles in craniofacial development. *Am J Med Genet A* **155A**: 270-279. <https://doi.org/10.1002/ajmg.a.33702>
- den Broeder MJ, Ballangby J, Kamminga LM, Alestrom P, Legler J, Lindeman LC, Kamstra JH. 2020. Inhibition of methyltransferase activity of enhancer of zeste 2 leads to enhanced lipid accumulation and altered chromatin status in zebrafish. *Epigenetics Chromatin* **13**: 5. <https://doi.org/10.1186/s13072-020-0329-y>

Dimitrova E, Turberfield AH, Klose RJ. 2015. Histone demethylases in chromatin biology and beyond. *EMBO Rep* **16**: 1620-1639. <https://doi.org/10.15252/embr.201541113>

Dixon MJ, Marazita ML, Beaty TH, Murray JC. 2011. Cleft lip and palate: understanding genetic and environmental influences. *Nat Rev Genet* **12**: 167-178. <https://doi.org/10.1038/nrg2933>

Flavahan WA, Gaskell E, Bernstein BE. 2017. Epigenetic plasticity and the hallmarks of cancer. *Science* **357**. <https://doi.org/10.1126/science.aal2380>

Gokbuget D, Belloch R. 2019. Epigenetic control of transcriptional regulation in pluripotency and early differentiation. *Development* **146**. <https://doi.org/10.1242/dev.164772>

Grosshans BL, Grotzsch H, Mukhopadhyay D, Fernandez IM, Pfannstiel J, Idrissi FZ, Lechner J, Riezman H, Geli MI. 2006. TEDS site phosphorylation of the yeast myosins I is required for ligand-induced but not for constitutive endocytosis of the G protein-coupled receptor Ste2p. *Journal of Biological Chemistry* **281**: 11104-11114. <https://doi.org/10.1074/jbc.M508933200>

Gurrieron C, Uriostegui M, Zurita M. 2017. Heterochromatin Reduction Correlates with the Increase of the KDM4B and KDM6A Demethylases and the Expression of Pericentromeric DNA during the Acquisition of a Transformed Phenotype. *J Cancer* **8**: 2866-2875. <https://doi.org/10.7150/jca.19477>

Han X, Feng J, Guo T, Loh YE, Yuan Y, Ho TV, Cho CK, Li J, Jing J, Janeckova E et al. 2021. Runx2-Twist1 interaction coordinates cranial neural crest guidance of soft palate myogenesis. *Elife* **10**. <https://doi.org/10.7554/eLife.62387>

Hanna CW, Demond H, Kelsey G. 2018. Epigenetic regulation in development: is the mouse a good model for the human? *Hum Reprod Update* **24**: 556-576. <https://doi.org/10.1093/humupd/dmy021>

He F, Chen Y. 2012. Wnt signaling in lip and palate development. *Front Oral Biol* **16**: 81-90. <https://doi.org/10.1159/000337619>

Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh H, Glass CK. 2010. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol Cell* **38**: 576-589. <https://doi.org/10.1016/j.molcel.2010.05.004>

Henckel A, Toth S, Arnaud P. 2007. Early mouse embryo development: could epigenetics influence cell fate determination? *Bioessays* **29**: 520-524. <https://doi.org/10.1002/bies.20591>

Hobbs CA, Chowdhury S, Cleves MA, Erickson S, MacLeod SL, Shaw GM, Shete S, Witte JS, Tycko B. 2014. Genetic epidemiology and nonsyndromic structural birth defects: from candidate genes to epigenetics. *JAMA Pediatr* **168**: 371-377. <https://doi.org/10.1001/jamapediatrics.2013.4858>

Hu N, Strobl-Mazzulla P, Sauka-Spengler T, Bronner ME. 2012. DNA methyltransferase3A as a molecular switch mediating the neural tube-to-neural crest fate transition. *Genes Dev* **26**: 2380-2385. <https://doi.org/10.1101/gad.198747.112>

Hu N, Strobl-Mazzulla PH, Bronner ME. 2014. Epigenetic regulation in neural crest development. *Dev Biol* **396**: 159-168. <https://doi.org/10.1016/j.ydbio.2014.09.034>

Jambhekar A, Dhall A, Shi Y. 2019. Roles and regulation of histone methylation in animal development. *Nat Rev Mol Cell Biol* **20**: 625-641. <https://doi.org/10.1038/s41580-019-0151-1>

Jiang W, Wang J, Zhang Y. 2013. Histone H3K27me3 demethylases KDM6A and KDM6B modulate definitive endoderm differentiation from human ESCs by regulating WNT signaling pathway. *Cell Res* **23**: 122-130. <https://doi.org/10.1038/cr.2012.119>

Jones NC, Lynn ML, Gaudenz K, Sakai D, Aoto K, Rey JP, Glynn EF, Ellington L, Du C, Dixon J et al. 2008. Prevention of the neurocristopathy Treacher Collins syndrome through inhibition of p53 function. *Nature Medicine* **14**: 125-133. <https://doi.org/10.1038/nm1725>

Kang S, Chovatiya G, Tumber T. 2019. Epigenetic control in skin development, homeostasis and injury repair. *Exp Dermatol* **28**: 453-463. <https://doi.org/10.1111/exd.13872>

Kim H, Kim D, Choi SA, Kim CR, Oh SK, Pyo KE, Kim J, Lee SH, Yoon JB, Zhang Y et al. 2018. KDM3A histone demethylase functions as an essential factor for activation of JAK2-STAT3 signaling pathway. *Proc Natl Acad Sci U S A* **115**: 11766-11771. <https://doi.org/10.1073/pnas.1805662115>

Kim KC, Friso S, Choi SW. 2009. DNA methylation, an epigenetic mechanism connecting folate to healthy embryonic development and aging. *J Nutr Biochem* **20**: 917-926. <https://doi.org/10.1016/j.jnutbio.2009.06.008>

Kim WT, Kim H, Katanaev VL, Joon Lee S, Ishitani T, Cha B, Han JK, Jho EH. 2012. Dual functions of DP1 promote biphasic Wnt-on and Wnt-off states during anteroposterior neural patterning. *EMBO J* **31**: 3384-3397. <https://doi.org/10.1038/emboj.2012.181>

Klemm SL, Shipony Z, Greenleaf WJ. 2019. Chromatin accessibility and the regulatory epigenome. *Nat Rev Genet* **20**: 207-220. <https://doi.org/10.1038/s41576-018-0089-8>

Kohn MJ, Bronson RT, Harlow E, Dyson NJ, Yamasaki L. 2003. Dp1 is required for extra-embryonic development. *Development* **130**: 1295-1305. <https://doi.org/10.1242/dev.00355>

Lee YH, Saint-Jeannet JP. 2011. Sox9 function in craniofacial development and disease. *Genesis* **49**: 200-208. <https://doi.org/10.1002/dvg.20717>

Leoyklang P, Suphapeetiporn K, Siriwan P, Desudchit T, Chaowanapanja P, Gahl WA, Shotelersuk V. 2007. Heterozygous nonsense mutation SATB2 associated with cleft palate, osteoporosis, and cognitive defects. *Hum Mutat* **28**: 732-738. <https://doi.org/10.1002/humu.20515>

Lessard JA, Crabtree GR. 2010. Chromatin regulatory mechanisms in pluripotency. *Annu Rev Cell Dev Biol* **26**: 503-532. <https://doi.org/10.1146/annurev-cellbio-051809-102012>

Levi G, Mantero S, Barbieri O, Cantatore D, Paleari L, Beverdam A, Genova F, Robert B, Merlo GR. 2006. Msx1 and Dlx5 act independently in development of craniofacial skeleton, but converge on the regulation of Bmp signaling in palate formation. *Mech Dev* **123**: 3-16. <https://doi.org/10.1016/j.mod.2005.10.007>

Li H. 2013. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. *arXiv:13033997v2 [q-bio.GN]*.

Li Y, Stockton ME, Bhuiyan I, Eisinger BE, Gao Y, Miller JL, Bhattacharyya A, Zhao XY. 2016. MDM2 inhibition rescues neurogenic and cognitive deficits in a mouse model of fragile X syndrome. *Sci Transl Med* **8**. <https://doi.org/10.1126/scitranslmed.aad9370>

Lindgren AM, Hoyos T, Talkowski ME, Hanscom C, Blumenthal I, Chiang C, Ernst C, Pereira S, Ordulu Z, Clericuzio C et al. 2013. Haploinsufficiency of KDM6A is associated with severe psychomotor retardation, global growth restriction, seizures and cleft palate. *Hum Genet* **132**: 537-552. <https://doi.org/10.1007/s00439-013-1263-x>

Lu S, Yang Y, Du Y, Cao LL, Li M, Shen C, Hou T, Zhao Y, Wang H, Deng D et al. 2015. The transcription factor c-Fos coordinates with histone lysine-specific demethylase 2A to

activate the expression of cyclooxygenase-2. *Oncotarget* **6**: 34704-34717.
<https://doi.org/10.18632/oncotarget.5474>

Madisen L, Zwingman TA, Sunkin SM, Oh SW, Zariwala HA, Gu H, Ng LL, Palmiter RD, Hawrylycz MJ, Jones AR et al. 2010. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. *Nat Neurosci* **13**: 133-140.
<https://doi.org/10.1038/nn.2467>

Manna S, Kim JK, Bauge C, Cam M, Zhao Y, Shetty J, Vacchio MS, Castro E, Tran B, Tessarollo L et al. 2015. Histone H3 Lysine 27 demethylases Jmjd3 and Utx are required for T-cell differentiation. *Nat Commun* **6**: 8152. <https://doi.org/10.1038/ncomms9152>

Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. 2000. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. *Genes Dev* **14**: 994-1004.

Miermont A, Antolovic V, Lenn T, Nichols JME, Millward LJ, Chubb JR. 2019. The fate of cells undergoing spontaneous DNA damage during development. *Development* **146**.
<https://doi.org/10.1242/dev.174268>

Mijit M, Caracciolo V, Melillo A, Amicarelli F, Giordano A. 2020. Role of p53 in the Regulation of Cellular Senescence. *Biomolecules* **10**. <https://doi.org/10.3390/biom10030420>

Molina-Serrano D, Kyriakou D, Kirmizis A. 2019. Histone Modifications as an Intersection Between Diet and Longevity. *Front Genet* **10**: 192.
<https://doi.org/10.3389/fgene.2019.00192>

Moller M, Schotanus K, Soyer JL, Haueisen J, Happ K, Stralucke M, Happel P, Smith KM, Connolly LR, Freitag M et al. 2019. Destabilization of chromosome structure by histone H3 lysine 27 methylation. *PLoS Genet* **15**: e1008093.
<https://doi.org/10.1371/journal.pgen.1008093>

Nakamura Y, Yamamoto K, He XJ, Otsuki B, Kim Y, Murao H, Soeda T, Tsumaki N, Deng JM, Zhang ZP et al. 2011. Wwp2 is essential for palatogenesis mediated by the interaction between Sox9 and mediator subunit 25. *Nature Communications* **2**.
<https://doi.org/10.1038/ncomms1242>

Nelms BL, Labosky PA. 2010. in *Transcriptional Control of Neural Crest Development*, San Rafael (CA).

Noden DM. 1983. The role of the neural crest in patterning of avian cranial skeletal, connective, and muscle tissues. *Dev Biol* **96**: 144-165. [https://doi.org/10.1016/0012-1606\(83\)90318-4](https://doi.org/10.1016/0012-1606(83)90318-4)

-. 1991. Cell movements and control of patterned tissue assembly during craniofacial development. *J Craniofac Genet Dev Biol* **11**: 192-213.

Parada C, Chai Y. 2012. Roles of BMP signaling pathway in lip and palate development. *Front Oral Biol* **16**: 60-70. <https://doi.org/10.1159/000337617>

Pediconi N, Salerno D, Lupacchini L, Angrisani A, Peruzzi G, De Smaele E, Levrero M, Belloni L. 2019. EZH2, JMJD3, and UTX epigenetically regulate hepatic plasticity inducing retro-differentiation and proliferation of liver cells. *Cell Death Dis* **10**: 518.
<https://doi.org/10.1038/s41419-019-1755-2>

Reynolds K, Kumari P, Sepulveda Rincon L, Gu R, Ji Y, Kumar S, Zhou CJ. 2019. Wnt signaling in orofacial clefts: crosstalk, pathogenesis and models. *Dis Model Mech* **12**.
<https://doi.org/10.1242/dmm.037051>

Rigueur D, Lyons KM. 2014. Whole-mount skeletal staining. *Methods Mol Biol* **1130**: 113-121.
https://doi.org/10.1007/978-1-62703-989-5_9

Rinon A, Molchadsky A, Nathan E, Yovel G, Rotter V, Sarig R, Tzahor E. 2011. p53 coordinates cranial neural crest cell growth and epithelial-mesenchymal transition/delamination processes. *Development* **138**: 1827-1838. <https://doi.org/10.1242/dev.053645>

Roessler E, Velez JI, Zhou N, Muenke M. 2012. Utilizing prospective sequence analysis of SHH, ZIC2, SIX3 and TGIF in holoprosencephaly probands to describe the parameters limiting the observed frequency of mutant gene x gene interactions. *Mol Genet Metab* **105**: 658-664. <https://doi.org/10.1016/j.ymgme.2012.01.005>

Ruijtenberg S, van den Heuvel S. 2016. Coordinating cell proliferation and differentiation: Antagonism between cell cycle regulators and cell type-specific gene expression. *Cell Cycle* **15**: 196-212. <https://doi.org/10.1080/15384101.2015.1120925>

Satokata I, Maas R. 1994. Msx1 deficient mice exhibit cleft palate and abnormalities of craniofacial and tooth development. *Nat Genet* **6**: 348-356. <https://doi.org/10.1038/ng0494-348>

Schwarz D, Varum S, Zemke M, Scholer A, Baggiolini A, Draganova K, Koseki H, Schubeler D, Sommer L. 2014. Ezh2 is required for neural crest-derived cartilage and bone formation. *Development* **141**: 867-877. <https://doi.org/10.1242/dev.094342>

Seelan RS, Mukhopadhyay P, Pisano MM, Greene RM. 2012. Developmental epigenetics of the murine secondary palate. *ILAR J* **53**: 240-252. <https://doi.org/10.1093/ilar.53.3-4.240>

Sen R, Lencer E, Geiger EA, Jones KL, Shaikh TH, Artinger KB. 2020. The role of KMT2D and KDM6A in cardiac development: A cross-species analysis in humans, mice, and zebrafish. *bioRxiv*: 2020.2004.2003.024646. <https://doi.org/10.1101/2020.04.03.024646>

Shahbazi MN, Jedrusik A, Vuoristo S, Recher G, Hupalowska A, Bolton V, Fogarty NNM, Campbell A, Devito L, Ilic D et al. 2016. Self-organization of the human embryo in the absence of maternal tissues. *Nat Cell Biol* **18**: 700-708. <https://doi.org/10.1038/ncb3347>

Shen X, Liu Y, Hsu YJ, Fujiwara Y, Kim J, Mao X, Yuan GC, Orkin SH. 2008. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. *Mol Cell* **32**: 491-502. <https://doi.org/10.1016/j.molcel.2008.10.016>

Shpargel KB, Starmer J, Wang C, Ge K, Magnuson T. 2017. UTX-guided neural crest function underlies craniofacial features of Kabuki syndrome. *Proc Natl Acad Sci U S A* **114**: E9046-E9055. <https://doi.org/10.1073/pnas.1705011114>

Smith ZD, Meissner A. 2013. DNA methylation: roles in mammalian development. *Nat Rev Genet* **14**: 204-220. <https://doi.org/10.1038/nrg3354>

Soares LM, He PC, Chun Y, Suh H, Kim T, Buratowski S. 2017. Determinants of Histone H3K4 Methylation Patterns. *Mol Cell* **68**: 773-785 e776. <https://doi.org/10.1016/j.molcel.2017.10.013>

Soldatov R, Kaucka M, Kastriti ME, Petersen J, Chontorotzea T, Englmaier L, Akkuratova N, Yang YS, Haring M, Dyachuk V et al. 2019. Spatiotemporal structure of cell fate decisions in murine neural crest. *Science* **364**: 971-+. <https://doi.org/10.1126/science.aas9536>

Sugii H, Grimaldi A, Li J, Parada C, Vu-Ho T, Feng J, Jing J, Yuan Y, Guo Y, Maeda H et al. 2017. The Dlx5-FGF10 signaling cascade controls cranial neural crest and myoblast interaction during oropharyngeal patterning and development. *Development* **144**: 4037-4045. <https://doi.org/10.1242/dev.155176>

Tateossian H, Morse S, Simon MM, Dean CH, Brown SD. 2015. Interactions between the otitis media gene, Fbxo11, and p53 in the mouse embryonic lung. *Dis Model Mech* **8**: 1531-1542. <https://doi.org/10.1242/dmm.022426>

Trainor P, Krumlauf R. 2000. Plasticity in mouse neural crest cells reveals a new patterning role for cranial mesoderm. *Nat Cell Biol* **2**: 96-102. <https://doi.org/10.1038/35000051>

Wiles ET, Selker EU. 2017. H3K27 methylation: a promiscuous repressive chromatin mark. *Curr Opin Genet Dev* **43**: 31-37. <https://doi.org/10.1016/j.gde.2016.11.001>

Williams AB, Schumacher B. 2016. p53 in the DNA-Damage-Repair Process. *Cold Spring Harb Perspect Med* **6**. <https://doi.org/10.1101/cshperspect.a026070>

Wilson S, Filipp FV. 2018. A network of epigenomic and transcriptional cooperation encompassing an epigenomic master regulator in cancer. *NPJ Syst Biol Appl* **4**: 24. <https://doi.org/10.1038/s41540-018-0061-4>

Wysocka J, Swigut T, Xiao H, Milne TA, Kwon SY, Landry J, Kauer M, Tackett AJ, Chait BT, Badenhorst P et al. 2006. A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling. *Nature* **442**: 86-90. <https://doi.org/10.1038/nature04815>

Xu J, Liu H, Lan Y, Aronow BJ, Kalinichenko VV, Jiang R. 2016. A Shh-Foxf-Fgf18-Shh Molecular Circuit Regulating Palate Development. *PLoS Genet* **12**: e1005769. <https://doi.org/10.1371/journal.pgen.1005769>

Young JI, Slifer S, Hecht JT, Blanton SH. 2021. DNA Methylation Variation Is Identified in Monozygotic Twins Discordant for Non-syndromic Cleft Lip and Palate. *Front Cell Dev Biol* **9**. <https://doi.org/10.3389/fcell.2021.656865>

Yu L, Gu S, Alappat S, Song Y, Yan M, Zhang X, Zhang G, Jiang Y, Zhang Z, Zhang Y et al. 2005. Shox2-deficient mice exhibit a rare type of incomplete clefting of the secondary palate. *Development* **132**: 4397-4406. <https://doi.org/10.1242/dev.02013>

Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum C, Myers RM, Brown M, Li W et al. 2008. Model-based analysis of ChIP-Seq (MACS). *Genome Biol* **9**: R137. <https://doi.org/10.1186/gb-2008-9-9-r137>

Zhao H, Oka K, Bringas P, Kaartinen V, Chai Y. 2008. TGF-beta type I receptor Alk5 regulates tooth initiation and mandible patterning in a type II receptor-independent manner. *Dev Biol* **320**: 19-29. <https://doi.org/10.1016/j.ydbio.2008.03.045>

Zoghbi HY, Beaudet AL. 2016. Epigenetics and Human Disease. *Cold Spring Harb Perspect Biol* **8**: a019497. <https://doi.org/10.1101/cshperspect.a019497>